The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma

Inclusion criteria

• ✓. Written informed consent must be obtained prior to any procedures that are not considered SOC
• ✓. ≥ 18 years old and ≤ 70 years old on the day of signing informed consent, male or female
• ✓. According to the WHO Classification of Tumors of the CNS (2021), definitely diagnosed recurrent or progressive GBM, WHO Grade 4, which must meet all 3 of the following criteria:
• ✓. Participants with either unresectable lesions, or with resectable lesions who have undergone prior surgical resection, or with resectable lesions and no planned reoperation within 3 months after enrollment based on Investigator's judgment
• ✓. Participants voluntarily provide the latest archival tumor or fresh biopsies FFPE samples (at least 8 consecutive non-stained sections) for B7H3 expression test by Immunohistochemistry (IHC), and the clinical pathology confirms positive B7H3 expression, defined as the proportion of 2+ and 3+ ≥ 20% (Reference refer to Appendix 13.1) or historical B7H3 positive expression within 12 months at the time of enrollment
• ✓. Karnofsky Performance Status (KPS) score ≥ 60
• ✓. Life expectancy of ≥ 12 weeks
• ✓. Adequate organ and marrow functions as defined below: (blood transfusion, blood component transfusion, or hematopoietic stimulating factors within 7 days prior to the first dose is not allowed)